SequelSEC

Equillium, Inc. EQ

Pharmaceutical Preparations · CIK 0001746466 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$41.10M
Fiscal year ended 2024-12-31
Operating income
-$8.27M
Fiscal year ended 2024-12-31
Free cash flow
-$19.11M
Fiscal year ended 2024-12-31

Valuation, from the filing

Public float$7.10MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.11Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.2%16th
Operating margin-20.1%70th
SBC / revenue9.1%33th
Net margin-19.6%66th
Revenue YoY growth13.9%61th
FCF margin-46.5%57th
Current ratio3.93x52th

Equillium, Inc. (EQ) reported revenue of $41.10M and net income of -$8.07M for the fiscal year ended 2024-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Equillium, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Equillium, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Revenue$41.10M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$8.27M
Net income-$8.07M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$361.00K
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$11.94M
Selling & marketingUnavailable

Balance

Equillium, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Cash & equivalents$18.08M
Total assets$25.60M
Current assets$24.98M
Total liabilities$6.54M
Current liabilities$6.36M
Total equity incl. NCI$19.06M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$0
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$2.68M

Cash flow

Equillium, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Operating cash flow-$19.03M
Capital expenditures$85.00K
Investing cash flow$13.81M
Financing cash flowUnavailable
Net change in cash-$5.13M
Stock-based compensation$3.75M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Equillium, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Free cash flow-$19.11M
Gross marginUnavailable
Operating margin-20.1%
FCF margin-46.5%
SBC / revenue9.1%
Current ratio3.93x
Revenue YoY growth13.9%
Net margin-19.6%
R&D / revenueUnavailable
CapEx / revenue0.2%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open EQ in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.